Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii.
about
Analysis of the Caenorhabditis elegans innate immune response to Coxiella burnetiiCoxiella burnetii phase I and II variants replicate with similar kinetics in degradative phagolysosome-like compartments of human macrophagesAntibody-mediated immunity to the obligate intracellular bacterial pathogen Coxiella burnetii is Fc receptor- and complement-independent.Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding moleculeMolecular pathogenesis of the obligate intracellular bacterium Coxiella burnetiiCoxiella burnetii induces apoptosis during early stage infection via a caspase-independent pathway in human monocytic THP-1 cellsChromosomal DNA deletions explain phenotypic characteristics of two antigenic variants, phase II and RSA 514 (crazy), of the Coxiella burnetii nine mile strain.Role of B cells in host defense against primary Coxiella burnetii infection.Primary Role for Toll-Like Receptor-Driven Tumor Necrosis Factor Rather than Cytosolic Immune Detection in Restricting Coxiella burnetii Phase II Replication within Mouse MacrophagesAdaptive immunity to the obligate intracellular pathogen Coxiella burnetiiCoxiella burnetii - Pathogenic Agent of Q (Query) Fever.Coxiella burnetii inhibits activation of host cell apoptosis through a mechanism that involves preventing cytochrome c release from mitochondria.Role of YadA, Ail, and Lipopolysaccharide in Serum Resistance of Yersinia enterocolitica Serotype O:3.Dot/Icm-translocated proteins important for biogenesis of the Coxiella burnetii-containing vacuole identified by screening of an effector mutant sub-library.Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation.
P2860
Q28818232-09488778-AF48-471E-B65E-E7DC5C4A3C21Q30495882-EC163FB5-FD16-4CF4-9426-63A4268663DCQ33441877-A9CA09A6-C566-449D-BE71-A00D85AD6028Q33853918-1172CDC5-A762-4B33-A820-0B00043D54F7Q34049976-A7D9717C-F018-4B02-90FE-A7E4633D371CQ34150024-9C4861BB-364C-4CA3-85C1-0EE6FE8F233FQ34258745-1BCBC339-130A-4CEB-80FF-EB917663B0FFQ36281310-66D1BB85-2375-48E9-B6C8-A5B39A45DCEEQ36728043-F1DA72D2-1D1D-4114-9ECE-65BCA4346C19Q37278126-E0B38C44-144B-46C7-8F2C-8B4D5B38F1F7Q37630321-E85E8DA2-F589-4C6A-9D74-82C72DBC8A42Q40441498-A1D38EF4-238A-47D6-B4D2-6D50C6247995Q41459015-5FACD1DD-8D91-415E-AA00-C9D8F25CB08CQ48232386-D8396881-63C6-4010-86AB-94292A61A308Q52685085-3B6C5BA3-2751-4187-B6B0-794D3C136B18
P2860
Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Lipopolysaccharide phase varia ...... tibility of Coxiella burnetii.
@en
type
label
Lipopolysaccharide phase varia ...... tibility of Coxiella burnetii.
@en
prefLabel
Lipopolysaccharide phase varia ...... tibility of Coxiella burnetii.
@en
P2860
P1476
Lipopolysaccharide phase varia ...... tibility of Coxiella burnetii.
@en
P2093
Hackstadt T
Vishwanath S
P2860
P407
P577
1988-01-01T00:00:00Z